BioSpace News Archive

Veloxis Pharmaceuticals A/S is pleased to announce the publication of Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients in the March 2018 issue of the American Journal of Kidney Diseases.

GroundFloor Media (GFM) and its sister agency, CenterTable, announced today a call for Spring 2018 grant applications by Denver-area nonprofits serving at-risk youth.

In response to the budget tabled by Ontario Finance Minister Charles Sousa, Innovative Medicines Canada welcomes the creation of the Ontario Drug and Dental Program and the expansion of OHIP + to seniors.

Kazia Therapeutics Limited is pleased to announce commencement of an international phase II clinical trial of its lead program, GDC-0084.

A man from Vancouver, Washington has filed a new Tasigna lawsuit accusing Novartis AG of failing to warn patients and doctors that the leukemia drug had been linked to severe, accelerated and irreversible atherosclerosis-related conditions.

Wize Pharma, Inc. announced it has enrolled the first patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome.

High Point Clinical Trials Center (HPCTC) and Amyndas Pharmaceuticals jointly announce the completion of the AMY-101 First in Human (FIH) study.

Biocept, Inc. reports financial results for the three and 12 months ended December 31, 2017, and provides an update on its business progress.

BioMarin Pharmaceutical Inc. announced that the European Medicines Agency (EMA) has accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase,

Five Prime Therapeutics, Inc. announced that it initiated patient dosing in its Phase 1 clinical trial of FPA150, a first-in-class immuno-oncology antibody that targets B7-H4.